Immuneering Inc. - IMRX Quarterly EPS earnings growth

Corporate company logo of Immuneering (IMRX)

Immuneering Corporation (IMRX) is scaling its portfolio of targeted inhibitors by developing AI-driven software tools. This activity leverages a biopharmaceutical ecosystem for cellular pathway modeling to create precision drugs. Simultaneously, the company is implementing green chemistry principles and energy efficiency. The growth rate of quarterly earnings per share illustrates the current trend, where the value of the indicator is 0.90.

immuneering.com (IMRX) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for Immuneering Corporation

- share price and consensus valuation forecast:
Fundamental company valuation:immuneering.com - IMRX
Flagship merchandise of immuneering.com

Quarterly EPS growth measures the trend of net income per share relative to previous periods. This metric reveals a business's ability to generate income amid market volatility. By analyzing the quarterly EPS change, an investor assesses the stability of the company's capital. For Immuneering Corporation (IMRX), this indicator reflects the efficiency of managing costs for expensive R&D research. The stability of these figures confirms the security of current resources during the development of solid tumor therapies.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Therapeutics) - Quarterly EPS earnings growth|Quarterly EPS earnings growth kymeratx.com|Year-over-year earnings per share growth for the last twelve months IDEAYA Biosciences, Inc. (IDYA)|ELVN (Enliven Therapeutics, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ORIC (ORIC Pharmaceuticals Inc)|Net earnings per share growth for the trailing year Relay Pharma|Nurix Therapeutics Inc - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tyra Biosciences|VSTM (Verastem, Inc.) - Year-over-year net earnings per share growth for the last 12 months|GLUE: Year-over-year earnings per share growth rate for the last twelve months|CGEM (cullinanoncology.com) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months C4 Tx CCCC|Quarterly EPS earnings growth BDTX|Repare Therapeutics Inc. - Year-over-year earnings per share growth for the last 12 months|PMV Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KPTI|PPCB: Year-over-year net earnings per share growth for the last 12 months|Cyclacel Pharmaceuticals - Year-over-year earnings per share growth rate for the last twelve months|AADI: Quarterly EPS earnings growth|Aileron Therapeutics Inc - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months glycomimetics.com GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks (SWTX)